Stockscreener 앱 받기
58.09
0.07%
-0.04
전일 마감가:
$58.13
열려 있는:
$58.36
하루 거래량:
2.31M
Relative Volume:
0.81
시가총액:
$9.65B
수익:
$1.06B
순이익/손실:
$-326.58M
주가수익비율:
-27.63
EPS:
-2.1022
순현금흐름:
$-977.73M
1주 성능:
-4.85%
1개월 성능:
+5.48%
6개월 성능:
-26.88%
1년 성능:
-2.12%
1일 변동 폭
$57.78
$58.96
1주일 범위
$57.47
$61.77
52주 변동 폭
$50.01
$86.74
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
명칭
Ionis Pharmaceuticals Inc
전화
(760) 931-9200
주소
2855 GAZELLE COURT, CARLSBAD, CA
Compare IONS vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
58.09 | 9.76B | 1.06B | -326.58M | -977.73M | -2.1022 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-21 | 개시 | Canaccord Genuity | Buy |
| 2026-04-10 | 재개 | Raymond James | Outperform |
| 2026-01-28 | 재개 | Barclays | Overweight |
| 2025-10-08 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2025-09-26 | 업그레이드 | Goldman | Sell → Neutral |
| 2025-09-03 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-31 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-01 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2025-04-07 | 개시 | H.C. Wainwright | Buy |
| 2025-03-31 | 개시 | Redburn Atlantic | Neutral |
| 2024-08-02 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-07-24 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-07-16 | 재개 | Jefferies | Buy |
| 2024-06-14 | 업그레이드 | Bernstein | Underperform → Mkt Perform |
| 2024-04-10 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2024-01-02 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-10-23 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2023-09-29 | 개시 | Raymond James | Strong Buy |
| 2023-07-31 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-06-07 | 재개 | Piper Sandler | Overweight |
| 2023-05-04 | 업그레이드 | Citigroup | Sell → Neutral |
| 2023-03-21 | 개시 | Bernstein | Underperform |
| 2022-12-21 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-09-09 | 재개 | Morgan Stanley | Overweight |
| 2022-07-18 | 재개 | Oppenheimer | Outperform |
| 2022-03-31 | 재개 | Piper Sandler | Overweight |
| 2022-03-01 | 개시 | Citigroup | Sell |
| 2022-03-01 | 개시 | Guggenheim | Buy |
| 2022-02-01 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2021-12-14 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2021-05-07 | 업그레이드 | UBS | Sell → Neutral |
| 2021-03-01 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2020-12-16 | 개시 | UBS | Sell |
| 2020-12-15 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2020-09-14 | 재개 | JP Morgan | Neutral |
| 2020-09-02 | 개시 | The Benchmark Company | Hold |
| 2020-06-01 | 재개 | Oppenheimer | Outperform |
| 2020-05-13 | 개시 | RBC Capital Mkts | Outperform |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2019-12-13 | 개시 | Oppenheimer | Outperform |
| 2019-11-13 | 개시 | BofA/Merrill | Buy |
| 2019-11-07 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2019-09-10 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2018-08-08 | 재확인 | Stifel | Hold |
| 2018-08-07 | 재확인 | Stifel | Hold |
| 2018-05-08 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2017-10-06 | 재개 | Goldman | Sell |
| 2017-08-17 | 개시 | Evercore ISI | Outperform |
| 2017-08-09 | 재확인 | Stifel | Hold |
| 2017-03-10 | 다운그레이드 | Goldman | Neutral → Sell |
| 2016-12-28 | 재확인 | BMO Capital Markets | Outperform |
| 2016-12-27 | 재확인 | Leerink Partners | Mkt Perform |
모두보기
Ionis Pharmaceuticals Inc 주식(IONS)의 최신 뉴스
Ionis Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:IONS) - MarketBeat
Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026 - BioSpace
IONS Looks 26.4% Overvalued on GF Value™ - GuruFocus
Why Is Ionis Pharmaceuticals (IONS) Pushing RG-6299 Into A Pivotal Phase III Trial? - Sahm
Ionis Pharmaceuticals (NASDAQ:IONS) Rating Increased to Hold at BMO Capital Markets - MarketBeat
Eagle Health Investments LP Acquires New Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
DCF Advisers LLC Purchases New Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Edmond DE Rothschild Holding S.A. Makes New Investment in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Great Lakes Advisors LLC Acquires Shares of 66,924 Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) Earns Market Perform Rating from Analysts at BMO Capital Markets - MarketBeat
This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For We - Benzinga
IONS Initiates Coverage On BMO Capital -- Price Target Announced at $60 - GuruFocus
BMO initiates Ionis Pharmaceuticals stock at Market Perform, PT $60 By Investing.com - Investing.com Canada
This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Sahm
IONS Looks 24.0% Overvalued on GF Value™ - GuruFocus
TimesSquare Capital Management LLC Takes $48.69 Million Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Grandfield & Dodd LLC Invests $2.94 Million in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Familial Amyloid Polyneuropathy Market - Future Market Insights
Ionis Pharma (IONS): FDA Catalysts, Accelerating Revenue And A Path To 2028 Cash-flow Breakeven - RTTNews
Piper Sandler Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Cuts Target Price to $94 - Moomoo
Ionis Pharmaceuticals (IONS) Stock Analysis: Exploring a 56% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Ionis Pharmaceuticals Inc (HAM:ISI) Stock Price, Trades & News - GuruFocus
Ionis Pharmaceuticals Trades at 10.9x Sales as Pipeline Optimism Clashes With Valuation Reality - finance.biggo.com
Ionis (IONS) Stock Looks Like A Bargain On Value But Full On Sales - Yahoo Finance
Empowered Funds LLC Increases Stock Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
ETFs Investing in Ionis Pharmaceuticals, Inc. Stocks - TradingView
Ionis Pharmaceuticals (IONS) Has A $92 Fair Value Narrative, Is The Stock A Bargain? - Yahoo Finance
IONS Stock Jumps 4% After-Hours — Goldman Sachs Lifts Price Target On Tryngolza Approval - stocktwits.com
Ionis Stock Has Plunged 30%. Is It Time to Buy the Beaten-Down Stock? - The Motley Fool
Ionis Stock Has Plunged 30%. Is It Time to Buy the Beaten-Down Stock? - The Motley Fool
Ionis Pharmaceuticals, Inc. $IONS Shares Bought by Handelsbanken Fonder AB - MarketBeat
(IONS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Ionis Pharmaceuticals, Inc. (IONS) Stock Analysis: Assessing Growth Potential with a 57.94% Upside - DirectorsTalk Interviews
IONS Investors Have Opportunity to Join Ionis Pharmaceuticals, Inc. Fraud Investigation with SBS Law - The AI Journal
Ionis Pharmaceuticals Inc. R (ISI.DU) Q1 FY2026 earnings call transcript - finance.yahoo.com
Ionis Pharmaceuticals, Inc. $IONS Shares Purchased by Dimensional Fund Advisors LP - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc.IONS - PR Newswire
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Ionis Pharmaceuticals, Inc. (IONS) Stock forecasts - Yahoo Finance UK
Michael Hayden Bought 34% More Shares In Ionis Pharmaceuticals - simplywall.st
Ionis Pharmaceuticals, Inc. (IONS) Stock Analysis: Exploring a 72% Potential Upside Amidst Challenging Metrics - DirectorsTalk Interviews
Ionis Pharmaceuticals, Inc. $IONS Stock Position Boosted by California State Teachers Retirement System - MarketBeat
Perceptive Advisors LLC Makes New $37.84 Million Investment in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Ionis Pharmaceuticals, Inc. (IONS) Stock Forecasts - Yahoo Finance
Ionis Earnings: Early Signs of Commercial Momentum for Tryngolza as Key Catalysts Approach - Morningstar
Groupama Asset Managment Purchases 57,651 Shares of Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
IONS5835891 Bond Profile — Key Metrics - TradingView
Ionis Pharmaceuticals (NASDAQ:IONS) Director Michael Hayden Buys 5,000 Shares - MarketBeat
Stempoint Capital LP Purchases New Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Ionis Pharmaceuticals Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Ionis Pharmaceuticals Inc (IONS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Ionis Pharmaceuticals Inc 주식 (IONS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Hayden Michael R | Director |
Jul 31 '26 |
Buy |
51.60 |
5,000 |
258,000 |
24,000 |
| HERMAN JOAN E | Director |
Jul 15 '26 |
Option Exercise |
0.00 |
5,220 |
0 |
51,306 |
| BERTHELSEN SPENCER R | Director |
Jul 15 '26 |
Option Exercise |
0.00 |
5,220 |
0 |
161,233 |
| BENNETT C FRANK | EVP, Chief Scientific Officer |
Jul 07 '26 |
Sale |
85.46 |
15,000 |
1,281,930 |
0 |
| BENNETT C FRANK | EVP, Chief Scientific Officer |
Jul 07 '26 |
Sale |
83.58 |
5,536 |
462,693 |
75,018 |
| Diaz Allene M. | Director |
Jul 07 '26 |
Option Exercise |
47.11 |
10,111 |
476,329 |
13,922 |
| Diaz Allene M. | Director |
Jul 07 '26 |
Sale |
85.42 |
10,111 |
863,637 |
3,811 |
| Kordasiewicz Holly B. | EVP, Chief Development Officer |
Jul 07 '26 |
Sale |
84.30 |
362 |
30,517 |
22,096 |
0.86%
0.31%
자본화:
|
볼륨(24시간):